Dimension Therapeutics Inc. (NASDAQ:DMTX) shares rose 4.4% during trading on Thursday . The company traded as high as $6.44 and last traded at $6.40, with a volume of 59,437 shares trading hands. The stock had previously closed at $6.13.

DMTX has been the topic of a number of research analyst reports. Goldman Sachs Group Inc. downgraded shares of Dimension Therapeutics from a “buy” rating to a “neutral” rating and set a $10.00 price objective on the stock. in a research note on Wednesday, March 30th. Zacks Investment Research cut shares of Dimension Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, March 29th. Citigroup Inc. dropped their target price on shares of Dimension Therapeutics from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Tuesday, March 29th. Canaccord Genuity reissued a “buy” rating on shares of Dimension Therapeutics in a report on Saturday, May 14th. Finally, Jefferies Group started coverage on shares of Dimension Therapeutics in a report on Thursday, June 2nd. They set a “buy” rating and a $12.00 target price on the stock. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $17.56.

The firm has a 50 day moving average price of $7.76 and a 200-day moving average price of $7.88. The stock’s market cap is $166.65 million.

Dimension Therapeutics (NASDAQ:DMTX) last issued its quarterly earnings data on Thursday, May 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.57) by $0.19. The company had revenue of $2.21 million for the quarter, compared to the consensus estimate of $2.24 million. Equities analysts expect that Dimension Therapeutics Inc. will post ($1.96) earnings per share for the current year.

In related news, SVP K. Reed Clark sold 5,000 shares of Dimension Therapeutics stock in a transaction dated Tuesday, June 7th. The stock was sold at an average price of $10.00, for a total value of $50,000.00. Following the completion of the transaction, the senior vice president now directly owns 5,000 shares of the company’s stock, valued at $50,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

An institutional investor recently bought a new position in Dimension Therapeutics stock. Jennison Associates LLC purchased a new position in shares of Dimension Therapeutics Inc. (NASDAQ:DMTX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 742,454 shares of the company’s stock, valued at approximately $8,265,000. Jennison Associates LLC owned 2.97% of Dimension Therapeutics as of its most recent SEC filing.

Dimension Therapeutics, Inc is a United States-based gene therapy company focused on developing novel treatments for rare diseases. The Company is focused on developing treatments for hemophilia A, hemophilia B and rare genetic diseases. The Company’s adeno-associated virus (AAV) vector technology enables for systemic administration of the gene therapy in vivo for the treatment of an array of single-gene rare diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.